ProKidney Corp. (PROK)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Bruce Culleton M.D.
|
CEO & Director | 1.18M | -- | 1969 |
|
Mr. James Coulston CPA
|
Chief Financial Officer | 724.87k | -- | 1977 |
|
Mr. Todd C. Girolamo Esq., J.D., M.B.A.
|
Chief Legal Officer & Secretary | 725.1k | -- | 1965 |
|
Mr. Kenneth Locke
|
Chief Technical Officer | -- | -- | -- |
|
Mr. Richard Williams
|
Chief Information Officer | -- | -- | -- |
|
Ms. Carla Poulson
|
Chief People Officer | -- | -- | -- |
|
Dr. Joseph M. Stavas M.D., M.P.H.
|
Senior Vice President of Interventional Procedures | -- | -- | -- |
|
Dr. Darin J. Weber Ph.D.
|
Chief Reg. Off, SVP and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access | -- | -- | 1968 |
|
Dr. Emily Butler Ph.D.
|
Senior VP of Biometric | -- | -- | -- |
|
Mr. Gregory P. Madison
|
Chief Commercial Officer | -- | -- | 1967 |
ProKidney Corp.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 231
Description
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Corporate Governance
Upcoming Events
November 9, 2026 at 9:00 PM UTC
ProKidney Corp. Earnings Date
Recent Events
November 5, 2025 at 12:00 AM UTC
DEL AM: Separately filed delaying amendment under Securities Act Rule 473 to delay effectiveness of a 1933 Act registration statement
